chronic heart failure

By Targets:	Angiotensin Receptor (4) Angiotensin-converting Enzyme (ACE) (4) Apoptosis (1) Endogenous Metabolite (3) Mineralocorticoid Receptor (3) MMP (2) Neprilysin (1) Potassium Channel (1) PPAR (2) TRP Channel (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (13) Endocrinology (2) Inflammation/Immunology (1) Metabolic Disease (4)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-120274

Balcinrenone AZD9977	Mineralocorticoid Receptor	Cardiovascular Disease Metabolic Disease
Balcinrenone (AZD9977) is a potent, selective, and orally active mineralocorticoid receptor (MR) modulator. Balcinrenone is used for heart failure, and chronic kidney disease research .

HY-145552

Azilsartan mepixetil QR-01019	Angiotensin Receptor	Cardiovascular Disease
Azilsartan mepixetil is the antagonist of angiotensin II receptor. Azilsartan mepixetil has stronger and longer blood pressure effect, more abvious and longer lasting heart rate lowering effect and high safety. Azilsartan mepixetil achieves ideal protective effect for heart and kidney functions. Azilsartan mepixetil has the potential for the research of hypertension, chronic heart failure and diabetic nephropathy (extracted from patent CN107400122A) .

HY-B1451

Imidapril hydrochloride TA-6366	Angiotensin-converting Enzyme (ACE) MMP	Cardiovascular Disease Metabolic Disease
Imidapril hydrochloride (TA-6366) is an orally active angiotensin-converting enzyme (ACE) and MMP-9 inhibitor. Imidapril hydrochloride suppresses the conversion of angiotensin I to angiotensin II and thereby reduces total peripheral resistance and systemic blood pressure. Imidapril hydrochloride can be used for hypertension, type 1 diabetic, nephropathy and chronic heart failure research .

HY-B1451A

Imidapril TA-6366 free base	Angiotensin-converting Enzyme (ACE) MMP	Cardiovascular Disease Metabolic Disease
Imidapril (TA-6366 free base) is an orally active angiotensin-converting enzyme (ACE) and MMP-9 inhibitor. Imidapril suppresses the conversion of angiotensin I to angiotensin II and thereby reduces total peripheral resistance and systemic blood pressure. Imidapril can be used for hypertension, type 1 diabetic, nephropathy and chronic heart failure research .

HY-B0251

Eplerenone 5 Publications Verification Epoxymexrenone	Mineralocorticoid Receptor Endogenous Metabolite	Cardiovascular Disease Cancer
Eplerenone (Epoxymexrenone) is a selective, highly specific and orally active aldosterone blocker (SAB). Eplerenone also is a selective mineralocorticoid receptor antagonist (MRA) with IC₅₀ value of 0.081 μM. Eplerenone can be used for the research of hypertension, atherosclerosis, chronic systolic heart failure (HF) and cardiovascular (CV) .

HY-123348

Sampatrilat UK-81252	Angiotensin-converting Enzyme (ACE) Neprilysin	Cardiovascular Disease Inflammation/Immunology
Sampatrilat (UK-81252) is a potent and orally active vasopeptidase inhibitor of ACE and neutral endopeptidase (NEP). Sampatrilat inhibits C-domain ACE (K_i=13.8 nM) 12.4-fold more potent than that for the N-domain (K_i=171.9 nM). Sampatrilat (UK-81252) can be used for the study of chronic heart failure and blood pressure regulation .

HY-U00209

Benzofurodil

Benfurodil; CB4091; Eudilat
Others Cardiovascular Disease

Benzofurodil is a cardiotonic, which is used for the chronic treatment of congestive heart failure.

Benzofurodil Benfurodil; CB4091; Eudilat	Others	Cardiovascular Disease
Benzofurodil is a cardiotonic, which is used for the chronic treatment of congestive heart failure.

HY-B0382

Fosinopril sodium 1 Publications Verification SQ28555	Angiotensin-converting Enzyme (ACE) Apoptosis	Cardiovascular Disease
Fosinopril Sodium is the ester prodrug of an angiotensin-converting enzyme (ACE) inhibitor, used for the treatment of hypertension and some types of chronic heart failure.

HY-137396

6β-Hydroxy Eplerenone	Endogenous Metabolite	Cardiovascular Disease
6β-Hydroxy Eplerenone is a metabolite of Eplerenone (HY-B0251). 6β-Hydroxy Eplerenone plays an important role in the research of hypertension, atherosclerosis, chronic systolic heart failure (HF) and cardiovascular (CV) .

HY-145552A

Azilsartan mepixetil potassium QR-01019K	Angiotensin Receptor	Metabolic Disease
Azilsartan mepixetil potassium (QR-01019K) is the antagonist of angiotensin II receptor. Azilsartan mepixetil potassium has stronger and longer blood pressure effect, more abvious and longer lasting heart rate lowering effect and high safety. Azilsartan mepixetil potassium has the potential for the research of hypertension, chronic heart failure and diabetic nephropathy (extracted from patent CN107400122A) .

HY-B0205

Candesartan 4 Publications Verification CV 11974	Angiotensin Receptor PPAR	Cardiovascular Disease Endocrinology Cancer
Candesartan (CV 11974) is an orally active angiotensin II AT1-Receptor blocker and PPAR-γ agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI) .

HY-A0154

Deslanoside Deacetyllanatoside C; Desacetyllanatoside C
Deslanoside (Desacetyllanatoside C) is a rapidly acting cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation. Deslanoside inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations .

HY-147357

TRPC3/6-IN-1	TRP Channel	Cardiovascular Disease
TRPC3/6-IN-1 is a potent selectivity blocker of the canonical transient receptor channels (TRPC3/6), has block potency for hTRPC3 and hTRPC6 with IC₅₀ values of 1260 nM and 500 nM, respectively. TRPC3/6-IN-1 can be used for the research of chronic models of heart failure .

HY-B0251R

Eplerenone (Standard) Epoxymexrenone (Standard)	Mineralocorticoid Receptor Endogenous Metabolite	Cardiovascular Disease Cancer
Eplerenone (Standard) is the analytical standard of Eplerenone. This product is intended for research and analytical applications. Eplerenone (Epoxymexrenone) is a selective, highly specific and orally active aldosterone blocker (SAB). Eplerenone also is a selective mineralocorticoid receptor antagonist (MRA) with IC₅₀ value of 0.081 μM. Eplerenone can be used for the research of hypertension, atherosclerosis, chronic systolic heart failure (HF) and cardiovascular (CV) .

HY-B0205R

Candesartan (Standard) CV 11974 (Standard)	Angiotensin Receptor PPAR	Cardiovascular Disease Endocrinology Cancer
Candesartan (Standard) is the analytical standard of Candesartan. This product is intended for research and analytical applications. Candesartan (CV 11974) is an orally active angiotensin II AT1-Receptor blocker and PPAR-γ agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI) .

HY-P0190A

Iberiotoxin TFA	Potassium Channel	Others
Iberiotoxin (TFA) is a selective high conductance high conductance Ca ²⁺-activated K ⁺ channel inhibitor with a K_d of ~1 nM. Iberiotoxin (TFA) does not block other types of voltage-dependent ion channels .

Cat. No.	Product Name

HY-L087

Anti-Obesity Compound Library	2338 compounds
Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries. MCE Anti-Obesity Compound Library owns a unique collection of 2338 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

Anti-Obesity Compound Library

2338 compounds

Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries.

MCE Anti-Obesity Compound Library owns a unique collection of 2338 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

Cat. No.	Product Name	Target	Research Area

HY-P0190A

Iberiotoxin TFA	Potassium Channel	Others
Iberiotoxin (TFA) is a selective high conductance high conductance Ca ²⁺-activated K ⁺ channel inhibitor with a K_d of ~1 nM. Iberiotoxin (TFA) does not block other types of voltage-dependent ion channels .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0251

Eplerenone 5 Publications Verification Epoxymexrenone	Cardiovascular Disease Structural Classification Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Steroids Cancer	Mineralocorticoid Receptor Endogenous Metabolite
Eplerenone (Epoxymexrenone) is a selective, highly specific and orally active aldosterone blocker (SAB). Eplerenone also is a selective mineralocorticoid receptor antagonist (MRA) with IC₅₀ value of 0.081 μM. Eplerenone can be used for the research of hypertension, atherosclerosis, chronic systolic heart failure (HF) and cardiovascular (CV) .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products